FORM PTO-1449 (Modified)

(37 CFR § 1.98(b))

partment of Commerce

(Usc Several Sheets If Necessary)

Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT

CA-13144 Attomey Docket No. Serial No.: 10/578,943

Applicant: Soo-Hyun Kim et al. Filing or 371(c) Date: 11/09/2006

Group Art Unit: 1647

U.S. PATENT DOCUMENTS Examine Cite Document / Publication / Class Subclass Filing Date Applicant / Patentee Patent Number Issue Date 6.277.969 08/21/2001 Le et al 536 23 1 08/12/1998 188 23 12/13/2000 6,448,380 09/10/2002 Rathjen et al 530 MAR 0 7 2001 6.572,852 06/03/2003 Smith et al. 424 85.2 01/12/2001 08/12/2003 Novick et al 424 184.1 10/12/2000 6,605,280 6,706,491 03/16/2004 Chang et al 435 29 11/29/1999 TRADEM 6 6 080 262 01/24/2006 Beianin et al. 435 226 11/13/2001 06/12/2002 2003/0087270 05/08/2003 Schlegel et al 435 6 2003/0092616 05/15/2003 Matsuda et al. 514 12 05/24/2002 8 08/01/2002 2003/0148316 08/07/2003 Lipford et al. 435 6 2003/0154032 08/14/2003 Pittman et al. 702 20 12/17/2001 10 435 6 09/26/2002 11 2005/0048490 03/03/2005 Azimzai et al. 435 10/03/2002 12 2005/0130145 06/16/2005 Yue et al 6 07/31/2003 2005/0208496 09/22/2005 Ohtani et al 435 14 2006/0088532 04/27/2006 Alitalo et al 424 145.1 03/07/2003 FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS Translation Document Country / Patent Office Class Subclass Publication Date Number Yes No 15 WO 01/064886 09/07/2001 WIPO WIPO 16 WO 02/059260 08/01/2002 10/24/2002 WIPO 17 WO 02/083898 18 WO 02/096943 12/05/2002 WIPO х 19 WO 03/080640 10/02/2003 WIPO WIPO 20 WO 2005/016962 02/24/2009 21 WO 2006/071088 07/06/2006 WIPO EP 1487857 12/22/2004 EPO OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication) Banda et al.," Mechanisms of effects of complement inhibition in murine collagen-induced arthritis," Arthritis Rheum, 46:3065, 2002 23 24 Banda et al., "Mechanisms of inhibition of collagen-induced arthritis by murine 1L-18 binding protein," J Immunol, 170:2100-2105, 2003 Bendele et al., "Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor 25 necrosis factor receptor type 1 in animal models of rheumatoid arthritis," Arthritis Rheum, 43:2648-2659, 2000 26 Bernot et al., "A transcriptional map of the FMF region" Genomics, 50:147-160, 1998 27 Cohen, "Systemic Autoimmunity," in Paul (ed.) Fundamental Immunology, Lippincott-Raven Publishers: Philadelphia, pp. 1067-1088, 1999 28 Dahl et al., "Identification of a novel gene expressed in activated natural killer cells and T cells," J Immunol. 148:597-603, 1992 Davis et al., "Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type 1: a clinical 20 update," Ann Rhem Dis, 59Suppl1:i41-3, 2000 Faggioni et al., "IL-18-binding protein protects against lipopolysaccharide- induced lethality and prevents the development of Fas/Fas ligand-30 mediated models of liver disease in mice," J Immunol, 167:5913-5920, 2001 31 Firestein, "Rheumatoid Arthritis," in Scientific American Medicine, 2000

/Elly Gerald Stoica/ Examiner:

Date Considered:

	_	\	
			Sheet 2 of
FORM PTO-1449 (Modified)	U.S epartment of Commerce Patent and Trademark Office	Attorney Docket No. 1CA-13144	Serial No.: 10/578,943
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Usc Several Sheets If Necessary) (37 CFR § 1.98(b))		Applicant: Soo-Hyun Kim et al.	
		Filing or 371(c) Date: 11/09/2006	Group Art Unit: 1647
32	Panelli et al., "Gene-expression profiling of the response of per administration" Genome Biol, 3(7):research0035.1-0035.17, 200		ma metastases to systemic IL-2
33	Gracie et al., "A proinflammatory role for IL-18 in rheumatoid arthritis," J Clin Invest, 104:1393-1401, 1999		
34	Steed et al., "Inactivation of TNF signaling by rationally designed dominant-negative TNF variants," Science, 301:1895-1898, 2003		
35	GenBank Accession No. AAH09401 GI:14424787 (2002)		
36	GenBank Accession No. AAH18782 GI:17511868 (2002)		
37	GenBank Accession No. AAS80144 GI:46095218 (2005)		
38	Dinarello and Kim, "IL-32, a novel cytokine with a possible role in disease," Ann Rheum Dis, 65(Suppl III):iii61-iii64, 2006		
39	Joosten et al., "IL-32, a proinflammatory cytokine in rheumatoid arthritis," Proc Natl Acad Sci USA, 103:3298-3303, 2006		
40	Kim et al., "Interleukin-32: A cytokine and inducer of TNFα," Immunity, 22:131-142, 2005		
41	Neto et al., "Shotgun sequencing of the human transcriptome with ORF expressed sequence tags," Proc Natl Acad Sci USA, 97:3491-3496, 2000		
42	Plater-Zyberk et al., "Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis," J Clin Invest, 108 1825-1832, 2001		
43	Strausberg et al., "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequence," Proc Natl Acad Sci USA, 99:16899-16903, 2002		

Examiner: /Elly Gerald Stoica/ Date Considered: 05/28/2008

EXAMINER:Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.